Publicaciones en las que colabora con JOSÉ LUIS REVUELTA HERRERO (15)

2023

  1. Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882

  2. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy

    Frontiers in Oncology, Vol. 13

2022

  1. A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

    Frontiers in Oncology, Vol. 12

  2. A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital

    Frontiers in Public Health, Vol. 10

  3. Implantación de una metodología para evaluar patient‑reported outcomes en pacientes con cáncer de pulmón: Protocolo del estudio PeOpLe (Patient‑reported Outcomes in Lung cancer )

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 4, pp. 265-269

  4. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

    Expert Opinion on Drug Safety, Vol. 21, Núm. 1, pp. 107-119

  5. Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients

    Journal of Oncology Pharmacy Practice, Vol. 28, Núm. 5, pp. 1259-1263

  6. Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App

    Frontiers in Oncology, Vol. 12

2021

  1. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

    Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681

  2. Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective

    Frontiers in Oncology, Vol. 11

  3. Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease

    Journal of Oncology Pharmacy Practice, Vol. 27, Núm. 3, pp. 751-755

2020

  1. Risks and medication errors analysis to evaluate the impact of a chemotherapy compounding workflow management system on cancer patients’ safety

    Health Informatics Journal, Vol. 26, Núm. 3, pp. 1995-2010

2019

  1. Los medicamentos del futuro ya son una realidad: linfocitos T car

    Panorama actual del medicamento, Vol. 43, Núm. 423, pp. 469-476

  2. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice

    Expert Opinion on Drug Safety, Vol. 18, Núm. 9, pp. 861-868

2018

  1. Pazopanib-Associated Transient Ischemic Attack

    American journal of therapeutics, Vol. 25, Núm. 3, pp. e393-e394